Baxter International (NYSE:BAX - Get Free Report) announced its quarterly earnings results on Friday. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02, Briefing.com reports. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The company had revenue of $3.85 billion during the quarter, compared to analysts' expectations of $3.85 billion. During the same period in the previous year, the business earned $0.68 earnings per share. The firm's quarterly revenue was up 3.8% compared to the same quarter last year.
Baxter International stock traded down $1.40 during mid-day trading on Friday, reaching $34.64. The company's stock had a trading volume of 6,636,750 shares, compared to its average volume of 4,048,272. Baxter International has a twelve month low of $32.48 and a twelve month high of $44.01. The firm has a market cap of $17.67 billion, a price-to-earnings ratio of 7.13, a PEG ratio of 1.21 and a beta of 0.60. The business has a 50 day moving average price of $37.39 and a 200-day moving average price of $36.12. The company has a current ratio of 1.40, a quick ratio of 0.91 and a debt-to-equity ratio of 1.35.
Several analysts recently commented on BAX shares. Citigroup lifted their price objective on Baxter International from $38.00 to $40.00 and gave the stock a "neutral" rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. cut their target price on shares of Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. StockNews.com upgraded Baxter International from a "hold" rating to a "buy" rating in a research report on Tuesday, October 22nd. Wells Fargo & Company decreased their price target on shares of Baxter International from $44.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group lifted their price objective on shares of Baxter International from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $41.20.
View Our Latest Analysis on Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.